A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Effect of Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- 10 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jan 2019.
- 25 Jul 2016 Status changed from not yet recruiting to recruiting.
- 16 Jun 2016 New trial record